The National Cancer Institute awarded a 5-year, $458,021 Project Grant (R01CA285536) to Mayo Clinic to conduct research on maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastoma. The project aims to evaluate the mechanism of sensitivity to MDM2 inhibitors in MDM2-amplified glioblastoma, define the effects of the MDM2 inhibitor brigimadlin on cellular response to genotoxic stress, and explore strategies to enhance the therapeutic window for MDM2 inhibitors in...
The National Cancer Institute (NCI) awarded a $655,306 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to The Regents of the University of California, San Francisco (UCSF) to develop novel therapies for isocitrate dehydrogenase (IDH) mutant gliomas, a deadly form of brain cancer. The project aims to target reactive metabolite generation in IDH mutant gliomas by inhibiting the enzyme glyoxalase 1 (GLO1) in combination with radiation therapy. The researchers will...
The National Cancer Institute (NCI) awarded a $547,687 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Weill Medical College of Cornell University to develop small molecule inhibitors of the SLIT2/ROBO signaling pathway as a novel immunotherapy approach for treating glioblastoma, an aggressive brain cancer. The project aims to screen a chemical library to identify small molecule inhibitors of the SLIT2/ROBO interaction, which plays a role in creating an...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $670,904 to The Regents of the University of California, San Francisco (UCSF) to develop metabolic therapy and imaging for diffuse midline gliomas (DMGs), a devastating type of brain cancer in children. The research aims to identify and target the vulnerabilities induced by the H3K27M mutation that drives DMGs, specifically inhibiting the enzymes...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $997,410 to Arizona State University to develop MRI-based methods for detecting and differentiating invasive high-grade glioma (HGG) brain tumor subtypes. The specific aims are to: 1) establish and validate quantitative diffusion MRI signatures for the neuronal (NEU) and glycolytic/plurimetabolic (GPM) HGG subtypes based on their microstructural differences, and 2)...
The National Cancer Institute (NCI) awarded a $678,228 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The three-phase study will optimize, verify, and validate the GLISCAN assay, which aims to quantify tumor mutations (TERT C228T/C250T,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is focused on developing a "next-generation" precision adoptive T cell therapy approach to treat pediatric high-grade gliomas. The $474,656 award will fund research to evaluate the safety, efficacy, and immunological effects of this therapy in preclinical models, determine the capacity to isolate and expand antigen-specific T cells from pediatric patients, and conduct a Phase 1...
This Project Grant award, valued at $639,004 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to evaluate the safety and efficacy of a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The key research activities include: Collecting and analyzing pre- and post-treatment tumor tissue and peripheral blood samples to conduct comprehensive immuno-profiling using advanced...